JAZZ
Jazz Pharmaceuticals plc
NASDAQ · IEHealthcareBiotechnology
$243.47-1.64%
Price as of Jul 20, 2026
JAZZ growth
Jazz Pharmaceuticals plc growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +9.2%
- EBITDA
- -58.9%
- EBIT
- -16.9%
- EPS
- -94.8%
- Free cash flow
- -16.3%
- Operating cash flow
- -14.4%
Forward estimates
- Revenue
- +2.6%
- EBITDA
- +152.8%
- EPS
- +5724.9%
Three-year CAGR
- Revenue
- +5.3%
- EBITDA
- -58.0%
- EBIT
- -37.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +14.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.